(Reuters) – The lowest dose of Novo Nordisk’s weight-loss drug, Wegovy, was listed as available, the U.S. health regulator’s website showed on Wednesday.
Several doses of Novo’s GLP-1 therapies such as Wegovy and diabetes drug Ozempic, both chemically known as semaglutide, have been on the U.S. Food and Drug Administration’s shortage list since early 2022.
While all doses of Wegovy and Ozempic are now listed as available, they have not been removed from the regulator’s shortage list.
Novo Nordisk did not immediately respond to a Reuters request for comment.
Surging demand for therapies such as Wegovy and Ozempic has led the Danish drugmaker to ramp up supply.
Eli Lilly, which makes rival drugs Mounjaro and Zepbound, has invested billions of dollars in boosting their production.
The FDA removed Lilly’s drugs from its shortage list in September. The agency is currently reviewing its decision and has allowed customized, cheaper versions of the treatments to be produced in the meantime.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments